In a move set to strengthen its position in the high-growth biologics sector, pharmaceutical giant Cipla Limited announced on 2nd March 2026 that it has entered into a joint venture (JV) agreement with Kemwell Biopharma Private Limited.
The partnership aims to create a new powerhouse in India dedicated to the development, manufacturing, and global commercialisation of biologic products.
The new entity will be incorporated as a 60:40 joint venture, with Cipla holding the majority stake. Under the terms of the agreement, the JV partners will initially invest up to INR 10 crores into the company in proportion to their respective holdings.
For its initial subscription, Cipla will acquire 6,000 shares at a par value of INR 10 each.
The primary objective of this collaboration is to build a robust pipeline of biologics for global markets. The joint venture is mandated to handle the entire lifecycle of these complex medicines, including:
- Research & Development: Developing and applying for necessary product licenses.
- Manufacturing: Leveraging advanced facilities for large-scale production.
- Commercialisation: Importing, exporting, and marketing products across international borders.
The partnership brings together Cipla’s extensive market reach and Kemwell’s specialised technical expertise.
Kemwell Biopharma is recognised as a premier Asia-based biologics Contract Development and Manufacturing Organisation (CDMO).
Kemwell’s state-of-the-art Bangalore site is already US FDA-certified, featuring a 5,000-litre bioreactor capacity, sterile fill-finish capabilities, and advanced laboratories for protein therapeutics.
This infrastructure is expected to be a cornerstone for the JV’s ability to support both novel biologics and biosimilar programs.
The incorporation of the JV company is expected to proceed following the execution of this agreement, marking a new chapter in Cipla’s expansion strategy within the pharmaceutical industry.
Disclaimer: The information provided is for educational purposes only and does not constitute financial advice. We are not registered financial advisors. Please conduct your own research and consult a qualified advisor before making investment decisions. Any investment decisions you make based on this information are solely at your own risk.
